Undetectable Level of Prostate Specific Antigen (PSA) Nadir Predicts PSA Biochemical Failure in Local Prostate Cancer with Delayed-combined Androgen Blockade
نویسندگان
چکیده
منابع مشابه
PSA Screening in Prostate Cancer
Introduction: Prostate cancer is one of the most common cancers in Iranian men. PSA(prostate specific antigen) screening is a controversial issue because PSA screening leads to diagnose of patients with low risk prostate cancer who not only do not benefit from treatment but also suffer from complication caused by treatment. On the other hand, without prostate cancer screening, the rate of meta...
متن کاملPRODUCTIO N OF PROSTATE-SPECIFIC ANTIGEN (PSA) BY A BREAST CANCER CELL LINE, SK-Br-3
PSA is a 33-KDa serine protease that is produced predominantly by prostate epithelium. However, it has been shown that about 30-40% of female breast tumors produce PSA and its production is associated with the presence of estrogen and progesterone receptors. We have now developed a new tissue culture system to study PSA production in breast cancer and its association with prognostic factors...
متن کاملProstate-Specific Antigen (PSA) Test
• Prostate-specific antigen (PSA) is a protein produced by cells of the prostate gland. The PSA test measures the level of PSA in the blood (see Question 1). • The U.S. Food and Drug Administration (FDA) has approved the use of the PSA test along with a digital rectal exam to help detect prostate cancer in men age 50 and older. The FDA has also approved the PSA test to monitor patients with a h...
متن کاملprostate-specific antigen (psa) density and free to total psa ratio in diagnosing prostate cancer with prostate-specific anti¬gen levels of 4.0 ng/ml or less
background: we aimed to value the usefulness of free to total prostate-specific antigen and prostate-specific antigen (psa) density for prostate cancer in the patients with psa levels of 4.0 ng/ml or less. methods: a total of 343 subjects with psa levels of 4.0 ng/ml or less were biopsied. all patients were divided into four groups according to the psa levels: 0 to 1.0 ng/ml, 1.1 to 2.0 ng/ml, ...
متن کاملNadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
BACKGROUND Primary androgen deprivation therapy (PADT) is the most effective systemic therapy for patients with metastatic prostate cancer. Nevertheless, once PSA progression develops, the prognosis is serious and mortal. We sought to identify factors that predicted the prognosis in a series of patients with metastatic prostate cancer. METHODS Two-hundred eighty-six metastatic prostate cancer...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Japanese Journal of Clinical Oncology
سال: 2008
ISSN: 0368-2811,1465-3621
DOI: 10.1093/jjco/hyn071